Prednisone
Treatment for Interstitial Lung Disease And Pulmonary Sarcoidosis
Typical Dosage: 20-40 mg daily, tapered
Effectiveness
75%
Safety Score
50%
Clinical Trials
8
Participants
2M
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
20-40 mg daily, tapered
Time to Effect
Days to 2 weeks
Treatment Duration
Months to years
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$750
Side Effect Mgmt:$1,200
Total Annual:$2,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
Outcome-Based Costs
Cost per Responder
$2,800
Cost per Remission
$5,250
Prednisone Outcomes
for Interstitial Lung Disease And Pulmonary Sarcoidosis
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Remission Rate
+40%
Common Side Effects
Weight gain
+80%
Mood changes
+50%
Insomnia
+40%
Hyperglycemia
+30%
Increased infection risk
+20%
Osteoporosis (long-term)
+15%
Sources:
Active Clinical Trials
2 active trials recruiting for Prednisone in Interstitial Lung Disease And Pulmonary Sarcoidosis
Effectiveness of Methotrexate Versus Prednisone as First-line Therapy for Pulmonary Sarcoidosis
NCT04314193ACTIVE NOT RECRUITINGPHASE4
138 participants
INTERVENTIONAL
's-Hertogenbosch, Netherlands +16 more
Started: Jun 1, 2020
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
NCT05841758RECRUITINGPHASE4
140 participants
INTERVENTIONAL
Avignon, France +20 more
Started: Jul 30, 2024
Completed Clinical Trials
4 completed trials for Prednisone in Interstitial Lung Disease And Pulmonary Sarcoidosis
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).
NCT02200146COMPLETEDPHASE3
94 participants
INTERVENTIONAL
Milan, Italy
Started: Mar 1, 2009
A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis
NCT03324503COMPLETEDNA
8 participants
INTERVENTIONAL
Birmingham, United States +19 more
Started: Dec 8, 2017
Diffuse Fibrotic Lung Disease
NCT00000596COMPLETEDPHASE2
INTERVENTIONAL
Started: Jun 1, 1978
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
NCT03793439COMPLETEDPHASE1
5 participants
INTERVENTIONAL
Portland, United States
Started: May 15, 2019